TIGIT and hepatocellular carcinoma: Hepatocellular carcinoma cells increase the expression of PVRL1, which suppresses cytotoxic T-cell activity through TIGIT, thereby promoting tumor resistance to PD1 inhibitors (Chiu et al., 2020).